Editorial on Evolving Role of Immune-oncology Therapeutics in GI Malignancies
The coming of age: immunotherapy in gastrointestinal malignancies
Abstract
Gastrointestinal (GI) cancers, including colorectal cancer (CRC), gastric-esophageal cancer (GEC), pancreatic adenocarcinoma (PAC), hepatocellular cancer (HCC) and cholangiocarcinoma (CCA), remain a major health problem worldwide. If detected early, given advancements in diagnostic strategies and multimodality therapeutic approaches with surgical resection, chemotherapy and/or radiation therapy, improvement in long term survival has been observed.
